Table 3.
Therapeutic nanoparticle-based neurotrophin targeting for AD
| No. | Nanocarrier | Neurotrophic factor | Model | References |
|---|---|---|---|---|
| 1 | Cubosome NPs | Gly 14-humanin | Rat | Wu et al., 2012 |
| 2 | Cationic liposomes | Plasmid encoding NGF or GDNF | In vitro | Lu et al., 2002 |
| 3 | PEGylated cationic lipid NPs | BDNF coding plasmid | In vitro | Angelov et al., 2011, 2012 |
| 4 | Fusion protein vectors | NGF-IgG; BDNF-IgG (OX26); GDNF-Tat | Rat | Bickel et al., 2001; Boado et al., 2007, 2011; Kabanov et al., 2007; Pardgridge et al., 2008, 2010 |
| 5 | Cubosome NPs with omega-3 fatty acid | BDNF | In vitro | Géral et al., 2012 |
| 6 | NTS (neurotensin)-polyplex nanocarrier | Neurotrophic genes (GDNF, NRTN, BDNF) | Rat, in vitro | Xie et al., 2005; Kuo et al., 2014; Rodrigues et al., 2020 |
| 8 | Polysorbate-coated poly (butyl cyanoacrylate) (PBCA) NPs | NGF | Mouse | Kurakhmaeva et al., 2009 |
| 9 | Nanoporous poly-L-glutamic acid (PGA) particles | BDNF | In vitro | Tan et al., 2012 |
AD: Alzheimer’s disease; BDNF: brain-derived neurotrophic factor; GDNF: glial cell-derived neurotrophic factor; NGF: nerve growth factor; NPs: nanoparticles; PEG: polyethylene glycol; Tat: transactivator of transcription.